Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia

Journal of Hospital Medicine

Volumn 6, Issue 7, 2011, Pages 405-410

  Micek, Scott T ^a   Welch, Emily C ^a   Khan, Junaid ^b   Pervez, Mubashir ^b   Doherty, Joshua A ^c   Reichley, Richard M ^c   Hoppe Bauer, Joan ^a   Dunne, W Michael ^a   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BJC HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CEFEPIME; CIPROFLOXACIN; HYPERTENSIVE FACTOR; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM IDENTIFICATION; BLOOD CULTURE; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052833587     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.899     Document Type: Article

References (30)

1. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115: 462-474.
2. Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med. 2003; 31: 2291-2301.
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003; 31: 2742-2751.
4. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003; 115: 529-535.
5. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med. 2009; 360: 439-443.
6. Boucher H, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 1-12.
7. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008; 47: S3-S13.
8. Barochia AV, Cui X, Vitberg D, et al. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2010; 38: 668-678.
9. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009; 180: 861-866.
10. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36: 296-327.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818-829.
12. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298: 1763-1771.
13. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29: 1303-1310.
14. Thiel SW, Asghar MF, Micek ST, Reichley RM, Doherty JA, Kollef MH. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med. 2009; 37: 819-824.
15. Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2007; 34: 2707-2713.
16. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
17. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. Wayne, PA: Clinical Laboratory Standards Institute; 2007.
18. D'Amato RF, Hochstein L, Vernaleo JR, et al. Evaluation of the BIOGRAM antimicrobial susceptibility test system. J Clin Microbiol. 1985; 22: 793-798.
19. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008; 46: 862-867.
20. Bhat SV, Peleg AY, Lodise TP Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother. 2007; 51: 4390-4395.
21. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005; 49: 1306-1311.
22. Trouillet JL, Chastre J, Vuagnat A. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998; 157: 531-539.
23. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006; 130: 787-793.
24. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008; 36: 737-744.
25. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome in Gram-negative sepsis: a retrospective analysis. Antimicrob Agents Chemother. 2010; 54: 1742-1748.
26. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997; 41: 1127-1133.
27. Bouza E, Torres MV, Radice C, et al. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis. 2007; 44: 382-387.
28. Oxacelay C, Ergani A, Naas T, et al. Rapid detection of CTX-M-producing Enterobacteriaceae in urine samples. J Antimicrob Chemother. 2009; 64: 986-989.
29. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46: 193-200.
30. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34: 1589-1596.